Atlas Trials

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

Clinical trial NCT02297529 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT02297529
Sponsor
Amgen
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Unresected Stage IIIB to IVM1c Melanoma

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.